Oxymetazoline hydrochloride 0.1% ophthalmic solution has Food & Drug Administration (FDA) approval for use in involution ptosis. It is an alpha 1 agonist and partial alpha 2 agonist that stimulates Muller’s muscle to lift the lid. The authors of this paper have trialled the use of this medication in patients with unilateral lid retraction associated with Graves’ Disease. The installation of drops is in the contralateral, pseudoptotic eye to encourage symmetry on the basis of Hering’s law. This would mean that there is a reduction of nerve impulses to both eyelids following drop administration, thus in theory lowering the retracted eyelid. The average pre-treatment marginal reflex distance 1 difference between right and left eyes was 2.46 and post-treatment this reduced to 0.39 (p<0.0001). Patients reported the medication lasted six to eight hours and 100% of patients were satisfied or very satisfied with the results. This is a very interesting option for thyroid eye disease, allowing rapid rehabilitation particularly in those who are unfit for surgery.